This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Thymosin β4 was well tolerated with no serious adverse events reported across doses.
Why it matters
Understanding the safety of thymosin β4 is crucial for its potential use in treating serious conditions like heart attacks. This study lays the groundwork for future research.
How the study worked
The study involved a randomized, double-blind design with healthy volunteers receiving single and multiple doses of thymosin β4.
What this study cannot tell us
The study was limited to healthy volunteers, and results may not apply to patients with specific conditions.
Read the original research
A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.
Journal of cellular and molecular medicine, 25(17), 8222-8228
Citation
Wang, Xinghe; Liu, Long; Qi, Lu; Lei, Chunpu; Li, Pu; Wang, Yu; Liu, Chen; Bai, Haihong; Han, Chengquan; Sun, Yinjian; Liu, Jincan. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.. Journal of cellular and molecular medicine, 25(17), 8222-8228. https://doi.org/10.1111/jcmm.16693